Accretion Nutraveda IPO is set to open on January 27, 2026, and will close on January 30, 2026. This SME IPO follows the Book Building route and aims to raise approximately ₹24.77 crores through a fresh issue. The issue price band is fixed between ₹122 and ₹129 per equity share with a face value of ₹10 each. The IPO is scheduled to list on BSE SME on February 4, 2026, while allotment is expected on February 2, 2026.
The company reported strong financial growth with revenue rising to ₹16.06 crores in FY2025 from ₹5.20 crores in FY2024. Profit after tax also surged to ₹2.61 crores in 2025 from ₹0.82 crores in 2024. Based on its performance, the IPO is recommended for long-term investors.
Contents
Accretion Nutraveda IPO Details
| Particulars | Details |
|---|---|
| IPO Open Date | January 27, 2026 |
| IPO Close Date | January 30, 2026 |
| Face Value | ₹10 per equity share |
| IPO Price Band | ₹122 – ₹129 per share |
| Issue Size | Approx ₹24.77 crores |
| Fresh Issue | Approx ₹24.77 crores |
| Issue Type | Book Build Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus | View PDF |
| RHP Draft Prospectus | View PDF |
| Anchor Investors | View PDF |
Accretion Nutraveda IPO
Open: 27-30 Jan
Issue Size: ₹24.77 Cr.
Objective: Raise funds to buy new & automated machinery and support working capital.
Exchange: BSE SME
Accretion Nutraveda IPO Review
Accretion Nutraveda IPO is an attractive opportunity for SME investors looking for long-term gains. With a strong revenue growth trajectory and profitability, the IPO has drawn attention from both institutional and retail investors.
The IPO allocation is well-balanced with 50% reserved for QIBs, 35% for retail investors, and 15% for HNIs. The minimum retail lot size is 2,000 shares amounting to ₹2,58,000, making it suitable for serious long-term investors.
Market Lot and Application Details
| Investor Category | Minimum Shares | Maximum Shares | Amount (₹) |
|---|---|---|---|
| Retail | 2,000 | 2,000 | 2,58,000 |
| S-HNI | 3,000 | 7,000 | 3,87,000 – 9,03,000 |
| B-HNI | 8,000 | – | 10,32,000 |
IPO Reservation
| Investor Category | Shares Offered | % of Shares |
|---|---|---|
| Anchor Investor | – | – |
| QIB (Ex. Anchor) | 9,08,000 | 47.29% |
| NII | 2,76,000 | 14.37% |
| Retail | 6,40,000 | 33.33% |
Accretion Nutraveda IPO Key Dates
| Event | Date |
|---|---|
| IPO Open | January 27, 2026 |
| IPO Close | January 30, 2026 (5 PM Cut-off) |
| Basis of Allotment | February 2, 2026 |
| Refunds | February 3, 2026 |
| Credit to Demat Account | February 3, 2026 |
| IPO Listing Date | February 4, 2026 |
Promoters and Holding Pattern
Promoters: Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod, and Mr. Vivek Ashok Kumar Patel.
| Particular | Shares | % Shareholding |
|---|---|---|
| Promoter Holding Pre-Issue | 53,20,000 | 100% |
| Promoter Holding Post-Issue | 72,40,000 | 73.48% |
Objects of the Issue
The proceeds from the Accretion Nutraveda IPO will be primarily used to enhance the company’s manufacturing capabilities and meet working capital requirements.
Funds will be utilised for purchasing machinery for automation in the existing unit, setting up new manufacturing facilities, and supporting day-to-day operational needs. The balance of the funds will be applied towards general corporate purposes to strengthen the company’s long-term growth and operational efficiency.
About Accretion Nutraveda Company
Accretion Nutraveda Limited is an Ahmedabad-based company engaged in manufacturing Ayurvedic and nutraceutical products, including tablets, capsules, liquids, powders, and oils. It operates as a Contract Development and Manufacturing Organization (CDMO) for domestic and international markets, focusing on health and wellness segments like liver care, women’s health, bone and joint support, digestive health, and skincare.
The company combines traditional Ayurvedic formulations with modern nutraceutical science and continues to expand its manufacturing capabilities and product portfolio.
Accretion Nutraveda Financials (₹ in Crores)
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2023 | 3.07 | 2.78 | 0.28 | 4.06 |
| 2024 | 5.20 | 4.28 | 0.82 | 4.64 |
| 2025 | 16.06 | 12.87 | 2.61 | 10.86 |
Valuation – FY2025
| KPI | Value |
|---|---|
| ROE | 81.22% |
| ROCE | 36.98% |
| EBITDA Margin | 22.79% |
| PAT Margin | 16.33% |
| Debt to Equity Ratio | – |
| EPS (Basic) | ₹7.19 |
| Price/Earnings (P/E) | N/A |
| Return on Net Worth (RoNW) | 48.85% |
| Net Asset Value (NAV) | ₹14.72 |
Peer Comparison
| Company | EPS | P/E | RoNW % | NAV | Income (₹ Cr) |
|---|---|---|---|---|---|
| Walpar Nutritions Ltd. | 1.80 | 23.94 | 11.27% | 13.65 | 60.26 |
| Influx Healthtech Ltd. | 7.31 | 25.93 | 36.72% | 5.31 | 104.99 |
Lead Managers (Merchant Bankers)
Sobhagya Capital Options Pvt. Ltd.
Company Address
| Particulars | Details |
|---|---|
| Name | Accretion Nutraveda Ltd. |
| Address | 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, TaSanand, Ahmedabad, Gujarat, 382213 |
| Phone | +91-9904366177 |
| compliance@accretionnutraveda.com | |
| Website | http://www.accretionnutraveda.com |
IPO Registrar
| Particulars | Details |
|---|---|
| Name | Kfin Technologies Ltd. |
| Phone | 04067162222, 04079611000 |
| apl.ipo@kfintech.com | |
| Website | https://ipostatus.kfintech.com/ |
Accretion Nutraveda IPO FAQs
What is Accretion Nutraveda IPO?
It is an SME IPO aiming to raise ₹24.77 crores through a fresh issue priced between ₹122 and ₹129 per equity share. The IPO will list on BSE SME.
When will the IPO open and close?
The IPO opens on January 27, 2026, and closes on January 30, 2026.
What is the investor portion allocation?
QIB: 50%, NII: 15%, Retail: 35%.
How to apply for the IPO?
Applications can be submitted via ASBA through banks, UPI via brokers, or offline through stock brokers.
What is the minimum market lot?
Retail investors must apply for a minimum of 2,000 shares amounting to ₹2,58,000.
When will the allotment and listing happen?
Allotment date: February 2, 2026.
Listing date: February 4, 2026 on BSE SME.
Expert Comment
Accretion Nutraveda IPO appears well-suited for long-term investors looking at SME growth stories. With strong financial performance, clear fund utilisation plans, and an experienced promoter group, the IPO carries potential for stable returns. Investors should consider applying within their risk appetite, especially given the company’s promising revenue and profit trends.
